about
miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signalingRNA binding protein HuR regulates the expression of ABCA1.microRNAs and HDL life cycle.Long-term therapeutic silencing of miR-33 increases circulating triglyceride levels and hepatic lipid accumulation in miceMicroRNAs: a connection between cholesterol metabolism and neurodegeneration.Hematopoietic Akt2 deficiency attenuates the progression of atherosclerosis."Micromanaging" metabolic syndromeInhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides.MicroRNA-758 regulates cholesterol efflux through posttranscriptional repression of ATP-binding cassette transporter A1.The miR-199-dynamin regulatory axis controls receptor-mediated endocytosis.MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels.A regulatory role for microRNA 33* in controlling lipid metabolism gene expression.MicroRNA 33 regulates glucose metabolism.miR-27b inhibits LDLR and ABCA1 expression but does not influence plasma and hepatic lipid levels in miceGenome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis.Micro-RNAs and High-Density Lipoprotein Metabolism.microRNA regulation of lipoprotein metabolism.microRNAs in lipoprotein metabolism and cardiometabolic disorders.miRNA regulation of LDL-cholesterol metabolism.Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes.Controlled-release mitochondrial protonophore (CRMP) reverses dyslipidemia and hepatic steatosis in dysmetabolic nonhuman primates
P50
Q24627398-793F1AC1-4B0E-45A9-9BD6-B7585DC2F83BQ33653613-C287986B-B11D-4A23-86E2-3DBC55461EA2Q34248289-F9E2403E-B957-4997-86FD-8FC96A80C7D7Q34342477-30926A95-F9CF-424F-9571-20F707AE80C6Q34613640-AF0B0DC5-77A0-40F6-A1BA-2F8E4C21E209Q35039330-A1DD5DDF-CF57-4055-BE36-8F5B271E08B9Q35600727-85E33DC0-FD2E-46C4-BD13-A695F773DF3DQ35606800-BD726EE1-37E2-4997-A88E-4D566375CADBQ35819417-9CF2929C-1374-493B-95BD-1F2C3336E2D7Q36091102-962D8EAB-CC82-46EC-877C-5664C13F309CQ36459815-5058DA8F-7839-47BE-B70A-E6B565CB3D68Q36827108-C3A85389-3B1A-4B31-8D48-485D37BFBBCBQ37036352-309956B3-BD0C-496B-A5B7-A4032DC8D089Q37156570-BCCF587A-4242-4B62-BB01-A28D51ACBCCDQ37193633-1399DC1C-D700-4562-8B49-AB27A43E518BQ37650114-CE019C8D-5557-42E3-A241-40305DC183CEQ37650119-2D33946F-3E33-470B-987A-73FC6AA9CEC7Q37709886-AD0EBC7E-4A9D-4890-89B1-DB96B5F5948EQ38770213-3C79D6CF-990D-4F83-821F-926020D4F8D5Q40450408-02554DB2-9370-430D-B923-BF02E6951906Q90440177-F16686EC-7F12-49CD-B392-BA5479E97A79
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Leigh Goedeke
@ast
Leigh Goedeke
@en
Leigh Goedeke
@es
Leigh Goedeke
@nl
Leigh Goedeke
@sl
type
label
Leigh Goedeke
@ast
Leigh Goedeke
@en
Leigh Goedeke
@es
Leigh Goedeke
@nl
Leigh Goedeke
@sl
prefLabel
Leigh Goedeke
@ast
Leigh Goedeke
@en
Leigh Goedeke
@es
Leigh Goedeke
@nl
Leigh Goedeke
@sl
P106
P1153
42561259100
P31
P496
0000-0002-7690-1572